Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12687457 | 1.00 | SHBG (0.36) | SHBGTSHRCYP3A4KDM4EJAK2 | |
| SCHEMBL11888192 | 1.00 | SHBG (0.36) | SHBGTSHRCYP3A4KDM4EJAK2 | |
| SCHEMBL131878 | 0.86 | — | — | |
| SCHEMBL17252249 | 0.86 | JAK2 (0.31) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL10107071 | 0.86 | JAK2 (0.31) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL17253449 | 0.86 | JAK2 (0.31) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL14359930 | 0.85 | — | — | |
| SCHEMBL5552795 | 0.83 | — | — | |
| SCHEMBL19749310 | 0.81 | SHBG (0.31) | SHBG | |
| SCHEMBL8616249 | 0.79 | ESR1 (0.34) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2024-03-05 | — | — | US | disclosed |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2022-09-29 | — | — | US | disclosed |
| WO-2022197641-A1 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL-AMINE DERIVATIVES AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS AND/OR INHIBITORS FOR THE TREATMENT OF CANCER AND OTHER DISEASES | RAPT THERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | FIRMENICH INCORPORATED (US) | 2022-05-24 | — | — | US | disclosed |
| US-11208595-B2 | Liquid-crystalline compounds | MERCK PATENT GMBH (DE) | 2021-12-28 | — | — | US | disclosed |
| US-20200299580-A1 | LIQUID-CRYSTALLINE COMPOUNDS | MERCK PATENT GMBH (DE) | 2020-09-24 | — | — | US | disclosed |
| EP-2862856-B1 | IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS | MITSUBISHI TANABE PHARMA CORP (JP) | 2018-08-01 | — | — | EP | disclosed |
| US-20170362509-A1 | POLYMERIZABLE COMPOUND-CONTAINING LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2017-12-21 | — | — | US | disclosed |
| US-9809752-B2 | Liquid crystal display device | DIC CORPORATION (JP) | 2017-11-07 | — | — | US | disclosed |
| US-9777220-B2 | Polymerizable compound-containing liquid crystal composition and liquid crystal display device using the same | DIC CORPORATION (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CHISSO CORPORATION (JP) | 2011-04-14 | — | — | US | disclosed |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | BAYER CROPSCIENCE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | BAYER CROPSCIENCE AG (DE) | 2009-08-27 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-20070225303-A1 | 8-Oxoadenine Compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-09-27 | — | — | US | disclosed |
| US-7238692-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| WO-2007048545-A2 | ALKOXYALKYL SPIROCYCLIC TETRAMIC ACIDS AND TETRONIC ACIDS | BAYER CROPSCIENCE AG (DE) | 2007-05-03 | — | — | WO | disclosed |
| US-7169785-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11918582-B2 | Pyrazole pyrimidine compounds and uses thereof | DCK, MCL1, DTYMK | SHBG 4804/4885TSHR 4605/4885CYP3A4 3171/4885 |
| US-20110086185-A1 | POLYMERIZABLE LIQUID CRYSTAL COMPOUND AND ITS POLYMER | CCNT1, POF1B, CCND3 | SHBG 3494/4885TSHR 3371/4885CYP3A4 987/4885 |
| US-20070225303-A1 | 8-Oxoadenine Compound | TLR7, CCR8, TLR8 | SHBG 3284/4885TSHR 2378/4885CYP3A4 1622/4885 |
| US-20220305018-A1 | PYRAZOLE PYRIMIDINE COMPOUNDS AND USES THEREOF | DCK, MCL1, DTYMK | SHBG 4804/4885TSHR 4605/4885CYP3A4 3171/4885 |
| US-11339128-B2 | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers | TAS2R5, TAS2R4, TAS2R30 | SHBG 4040/4885TSHR 4224/4885CYP3A4 2398/4885 |
| US-11208595-B2 | Liquid-crystalline compounds | CHRM1, C1S, CHRM2 | SHBG 615/4885TSHR 1920/4885CYP3A4 89/4885 |
| US-20090215624-A1 | Alkoxyalkyl Spirocyclic Tetramic Acids and Tetronic Acids | DDT, TBCD, TBCA | SHBG 4098/4885TSHR 564/4885CYP3A4 149/4885 |
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | SHBG 4429/4885TSHR 4787/4885CYP3A4 3028/4885 |
| US-20200299580-A1 | LIQUID-CRYSTALLINE COMPOUNDS | CHRM1, C1S, CHRM2 | SHBG 615/4885TSHR 1920/4885CYP3A4 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.